Extensive functional evaluation of exon 20 insertion mutations of EGFR

Variability of EGFR exon 20 insertions in 24,468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors

(2020) YanRu Qin et al.   Molecular Oncology

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

(2019) Wenfeng Fang et al.   BMC CANCER

Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations

(2019) Jenn-Yu Wu et al.   Clinical Lung Cancer

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib

(2019) Ashiq Masood et al.   SEMINARS IN ONCOLOGY

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

(2019) B. van Veggel et al.   LUNG CANCER

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

(2018) Jacqulyne P. Robichaux et al.   NATURE MEDICINE

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Thanyanan Reungwetwattana et al.   JOURNAL OF CLINICAL ONCOLOGY

Altered conformational landscape and dimerization dependency underpins the activation of EGFR byαC–β4 loop insertion mutations

(2018) Zheng Ruan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer

(2017) Hai-Yan Tu et al.   LUNG CANCER

A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer

(2017) Shinji Kohsaka et al.   Science Translational Medicine

CompoundEGFRmutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma

(2016) Eun Young Kim et al.   CANCER BIOLOGY & THERAPY

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

(2016) Yoshihisa Kobayashi et al.   CANCER SCIENCE

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activatingEGFRmutations: Subgroup analysis of LUX-Lung 3

(2015) Terufumi Kato et al.   CANCER SCIENCE

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

(2015) James C-H Yang et al.   LANCET ONCOLOGY

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer

(2015) Toshiyuki Hirano et al.   Oncotarget

Prevalence, Clinicopathologic Characteristics, and Molecular Associations of EGFR Exon 20 Insertion Mutations in East Asian Patients with Lung Adenocarcinoma

(2014) Yunjian Pan et al.   ANNALS OF SURGICAL ONCOLOGY

Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors

(2014) Hyun Sun Woo et al.   INVESTIGATIONAL NEW DRUGS

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer

(2013) Bhumsuk Keam et al.   International Journal of Clinical Oncology

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

(2013) Geoffrey R. Oxnard et al.   Journal of Thoracic Oncology

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

(2013) M. E. Arcila et al.   MOLECULAR CANCER THERAPEUTICS

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

(2013) H. Yasuda et al.   Science Translational Medicine

Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations

(2012) Marius Lund-Iversen et al.   Journal of Thoracic Oncology

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

(2011) Hiroyuki Yasuda et al.   LANCET ONCOLOGY

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

(2010) Luis Paz-Ares et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Anticancer drug development: the grand challenges

(2010) William N. Hait   NATURE REVIEWS DRUG DISCOVERY

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

(2008) J.-Y. Wu et al.   CLINICAL CANCER RESEARCH

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE